What is a joint audit for Pharmaceutical Manufacturers?

02 Mar 2026

Supply chain solutions for pharma sector

In the dynamic landscape of pharmaceutical manufacturing, ensuring the quality and safety of raw materials and components is paramount to delivering safe and effective therapeutics. Manufacturers face increasing pressure from regulatory bodies to maintain stringent supplier management practices, including regular audits of suppliers' facilities and processes. This regulatory scrutiny, combined with the global distribution of suppliers, presents significant challenges for manufacturers conducting comprehensive and efficient supplier audits.

Pharmaceutical manufacturers typically manage a vast network of suppliers and service providers, each critical to producing pharmaceutical products. However, auditing all suppliers regularly is challenging and resource-intensive. Manufacturers often struggle with logistical constraints, varying regulatory requirements across regions, and the volume of audits needed to ensure compliance and quality assurance. For critical suppliers, there is an expectation that an on-site audit has been conducted to qualify them initially before purchasing materials for production. Numerous suppliers are situated in distant regions from their clients (such as India, China, and Eastern Europe), and there are cost and resource implications of sending their staff to accomplish these audits.

The Role of Joint Audits

Joint audits offer a strategic solution to these challenges. Multiple manufacturers can choose to join a joint audit carried out by an external audit partner. By grouping various customer requests into a single audit, the common objectives are examined only once, increasing the audit's efficiency. These audits can apply to a wide range of standards depending on the supplier and the product supplied, from Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) to ISO standards and more. This approach allows multiple manufacturers to share the costs of audits conducted by third-party auditing service providers. By consolidating audit efforts, joint audits streamline the auditing process and enhance efficiency in supplier management.

Key Benefits for Manufacturers

1. Cost Savings: Shared audit programs reduce audit-related expenses by dividing costs among participating manufacturers. This cost-sharing model allows manufacturers to allocate resources towards other critical operations or perhaps enabled them address other parts of their supplier audit program.
2. Operational Efficiency: Joint audits follow typically standardized audit protocols, ensuring consistency in audit outcomes across sponsor companies. Manufacturers benefit from reduce time to scheduling an audit and also improved turnaround times for audit reports. At Intertek, the audit scope can also be flexible and designed to meet the needs of the sponsor companies. Before the audit, sponsors can request special focus on the specific areas covered in the audits.
3. Regulatory Compliance: Joint audits help manufacturers meet regulatory requirements more effectively by ensuring comprehensive and consistent evaluations of supplier facilities and processes. This proactive approach supports compliance with global regulatory standards and reduces the risk of regulatory actions or product recalls.
4. Enhanced Supplier Relationships: Participating in joint audits demonstrates a commitment to transparency and collaboration with suppliers. Manufacturers can build stronger, trust-based relationships with suppliers based on shared quality, safety, and regulatory compliance goals.

Case Study: Intertek's Shared Audit Service

Intertek's shared audit service exemplifies the benefits of joint audits for pharmaceutical manufacturers. By leveraging Intertek's expertise and global presence, manufacturers can participate in joint audits that optimize resources and enhance audit effectiveness. This approach reduces supplier audit fatigue, strengthens supplier relationships, and supports continuous improvement in supplier quality management.

The key takeaway is that joint audits offer pharmaceutical manufacturers a strategic advantage in navigating the complexities of supplier management and regulatory compliance. By embracing collaborative audit solutions, manufacturers can achieve significant cost savings, improve operational efficiency, mitigate supply chain risks, and strengthen supplier partnerships. As the pharmaceutical industry evolves, joint audits will play an increasingly pivotal role in enhancing supply chain transparency, resilience, and overall business sustainability. Embracing collaborative audit solutions is essential for manufacturers committed to delivering high-quality, safe, and compliant pharmaceutical products to global markets.